Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Prostate. 2021 Sep 13;81(16):1382–1389. doi: 10.1002/pros.24236

Table 2.

PSA50 Response

Therapy Prior gATM gBRCA2 P
Abiraterone Overall 9/16 (56%) 11/19 (58%) >0.9
Pre-enza 9/14 (64%) 10/17 (59%)
Post-enza 0/2 ( 0%) 1/2 (50%)
Enzalutamide Overall 9/16 (56%) 8/12 (67%) 0.7
Pre-abi 7/10 (70%) 5/7 (71%)
Post-abi 2/6 (33%) 3/5 (60%)
Docetaxel Overall 9/13 (69%) 9/16 (56%) 0.7
Pre-abi/enza 7/9 (78%) 4/7 (57%)
Post-abi/enza 2/4 (50%) 5/9 (56%)
PARPi Overall 0/7 ( 0%) 12/14 (86%) <0.001
Pre-plat 0/3 ( 0%) 10/11 (91%)
Post-plat 0/4 ( 0%) 2/3 (67%)